Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Juvenile Idiopathic Arthritis (JUVE-X)
NCT03773965Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2019
- Primary completion
- Jul 2031
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, open-label, single-arm trial of baricitinib in juvenile idiopathic arthritis (JIA), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with One or More Serious Adverse Event(s) at 264 weeks and Number of Participants with Permanent Investigational Product Discontinuations at 264 weeks. Started Apr 2019; status: recruiting.
02
Drugs
baricitinib
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT03773965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03773965.